Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Telik, Inc.

Home Clinical Trial Sponsors and OrganizationsTelik, Inc.

Telik, Inc.

ACTIVE

加利福尼亚州圣克拉拉县, California, United Statestelik.comPrivate11–50 employeesEstablished: 1988-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

4

4 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

1988

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

1

25.0%

Trial Status Distribution

Active, not recruiting

4

100.0%

Clinical Trials

Trials sponsored by this organization (4)

A Clinical Trial to Compare the Effectiveness of TLK286 (Telcyta?) and Gefitinib (Iressa®) in Non-Small Cell Lung Cancer

Active, not recruiting

Apr 2012530 participants

Phase 3 randomized study of TLK286 (Telcyta™) in combination with liposomal doxorubicin (Doxil®/Caelyx®) versus liposomal doxorubicin (Doxil®/Caelyx®) as second-line therapy in platinum refractory or resistant ovarian cancer - ASSIST-5

Active, not recruiting

Feb 2006244 participants

Phase 3 randomized study of TLK286 (Telcyta™) in combination with liposomal doxorubicin (Doxil®/Caelyx®) versus liposomal doxorubicin (Doxil®/Caelyx®) as second-line therapy in platinum refractory or resistant ovarian cancer - ASSIST-5

Active, not recruiting

Feb 2006244 participants

Phase 3 Randomized Study of TLK286 versus Gefitinib(Iressa) as Third-Line Therapy in Locally Advanced orMetastatic Non-Small Cell Lung Cancer

Active, not recruiting

Mar 2005520 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials4
Approvals
News

Back to Organizations